彻底改变1型糖尿病管理:探索口服胰岛素和辅助治疗方法
Mohsen Nabi-Afjadi1, Samane Ostadhadi2, Mahsa Liaghat3
1Department of Biochemistry, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
概括
1型糖尿病 (T1D) 治疗方法正在进化,超越了注射. 研究探索口服胰岛素和基于免疫的疗法,以改善血糖控制和患者对T1D管理的遵守.
科学领域:
- 内分泌学和免疫学.
- 药理学和药物输送 药理学和药物输送
背景情况:
- 1型糖尿病 (T1D) 是一种慢性自身免疫性疾病,需要终身胰岛素治疗,通常是通过注射或.
- 目前的T1D治疗在患者遵守和实现最佳血糖控制方面面临挑战.
- 现有的治疗方法包括免疫集中治疗和非免疫调节辅助疗法.
研究的目的:
- 提供当前和新兴的1型糖尿病治疗选择的全面概述.
- 批判性地评估口服胰岛素作为注射更方便的替代品的潜力.
- 讨论开发针对T1D的定制免疫学和药理学干预措施的进展和挑战.
主要方法:
- 对免疫集中治疗的审查:抗原疫苗接种,细胞导向和细胞因子导向干预.
- 对非免疫调节辅助疗法的分析,包括甲型胺,GLP-1RA和SGLT抑制剂.
- 检查克服口服胰岛素输送障碍的策略,例如分子修饰和吸收增强.
主要成果:
- 口服胰岛素提供了潜在的好处,如改善患者的服从性和更稳定的血糖控制.
- 口服胰岛素仍然面临重大挑战,包括酶降解和消化道吸收不良.
- 辅助疗法是有前途的,但需要进一步的研究,以优化整合到T1D管理中.
结论:
- 尽管取得了进展,但T1D治疗需要进一步的创新来解决治疗复杂性的问题.
- 未来的研究应该优先考虑个性化免疫疗法,组合药物策略和精细的口服胰岛素配方.
- 最终的目标是实现卓越的血糖管理,并提高T1D患者的生活质量.
相关概念视频
01:15Diabetes: Management and Pharmacotherapy
265
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
265
01:22Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
01:16Insulin: Dosing Regimen and Adverse Effects
167
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
167
01:22Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
01:27Insulin Formulations: Types and Delivery
191
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
191
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
192
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192